Cisapride

  • Prepulsid
Formula
C23H29ClFN3O4
Structure
Description
White to slightly biege powder. Odorless.
Uses
Medication.

Registry Numbers and Inventories.
CAS
81098-60-4
EC (EINECS/ELINCS)
279-689-7
RTECS
CU9372000
RTECS class
Drug; Human Data
Merck
12,2377
Beilstein/Gmelin
3634146
Austrailia AICS
Listed

Properties.
Formula
C23H29ClFN3O4
Formula mass
465.95
Melting point, °C
107 - 111
Solubility in water
Insoluble

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
No data.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Exposure effects
with therapeutic use - headaches may commonly occur with oral cisapride administration. Seizures, insomnia, anxiety, extrapyramidal effects, and the appearance of neuroleptic malignant syndrome are rare occurrences associated with therapeutic administration of cisapride. Cisapride is classified as FDA Pregnancy Category C. <br>Cisapride is excreted in human breast milk.
   Inhalation
Bronchospasm is a rare occurrence associated with cisapride ingestion.
   Skin
Rashes and pruritus were uncommon effects following cisapride therapy.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

Transport.